spacer
home > epc > autumn 2009 > reduction, replacement, refinement
PUBLICATIONS
European Pharmaceutical Contractor

Reduction, Replacement, Refinement

Fifty years ago, two British scientists, William Russell and Rex Burch, published a book entitled The Principles of Humane Experimental Research (1). This book paved the way for an ethos now shared by many scientists, namely that there is a fundamental obligation on those who conduct experiments on sentient species to ensure that harm is kept to an absolute minimum. Here we look at how animal testing can be reduced in the context of the current research and testing climate.

DRIVING FORCES THAT INFLUENCE ANIMAL TESTING

Many factors influence trends in the use of animals in research, testing and training, including the societal, economic, and political and market climates. For instance, concerns over the safety of chemicals that, in some cases, have been in common use for many decades, has culminated in the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) legislation that threatens to demand the conduct of around four million animal tests for existing chemicals. The mere existence of the REACH legislation is a reflection of the increasing threat of litigation that has stemmed from improved public and scientific awareness of the potential harm caused by everyday exposure to chemicals. By the same token, societal pressure is a major factor in determining the provisions of the Cosmetics Directive 76/768/EEC that, by 2013, will prohibit testing of cosmetic and toiletry ingredients and that has already banned the EU marketing of products tested on animals. The provisions of the Cosmetics Directive have spurred the cosmetics industry to develop non-animal methods to replace animal tests. Similarly, the REACH legislation, with its tight implementation timelines and disconcerting animal welfare and financial burden, has encouraged stakeholders to examine how existing non-animal alternatives and information can be used to best effect.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer

Nirmala Bhogal graduated with a BSc (Hons) in Biochemistry and Pharmacology, a PhD in Biochemistry and Molecular Biology and a postgraduate degree in Law. Her expertise is in the preclinical development of small chemical drugs and protein hormone mimetics. Nirmala joined FRAME in 2004 and currently oversees the FRAME Research Programme, working closely with scientists within the FRAME Alternatives Laboratory based at the University of Nottingham. Her area of research focuses on the evaluation of medicinal products.

Rita Seabra graduated with a BSc in Biology from the University of Glamorgan, South Wales and undertook her PhD in the School of Pharmacy at the University of Nottingham. Her research career included work on wound healing. Her interests at FRAME include systems biology, immune modulation and genetically-altered animals.

Michelle Hudson graduated from the University of Sheffield with a Master degree in Zoology. Her main research interests are the application of methods to reduce the number of animals used in experiments, the refinement and regulation of animal procedures and the replacement of laboratory non-human primates.

spacer
Nirmala Bhogal
spacer
spacer
spacer
Rita Seabra
spacer
spacer
spacer
Michelle Hudson
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

PHASE II & IIa Clinical Trials

21-22 February 2012, Lancaster London Hotel, London

Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >>

 
News and Press Releases

AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC

AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.  
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.